WO2024246862 - CHEMICAL COMPOUNDS AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2024/246862
Publication Date
05.12.2024
International Application No.
PCT/IB2024/055353
International Filing Date
31.05.2024
Title **
[English]
CHEMICAL COMPOUNDS AND USES THEREOF
[French]
COMPOSÉS CHIMIQUES ET LEURS UTILISATIONS
Applicants **
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED
GSK Medicines Research Centre
Gunnels Wood Road
Stevenage SG1 2NY, GB
IDEAYA BIOSCIENCES, INC.
7000 Shoreline Court, Suite 350
South San Francisco, California 94080, US
Inventors
BRNARDIC, Edward
1250 South Collegeville Road
Collegeville, Pennsylvania 19426, US
CAMPBELL, Kira A.
1250 South Collegeville Road
Collegeville, Pennsylvania 19426, US
DEMARTINO, Michael P.
1250 South Collegeville Road
Collegeville, Pennsylvania 19426, US
LEISTER, Lara K.
1250 South Collegeville Road
Collegeville, Pennsylvania 19426, US
LYNCH-COLAMETA, Tessa
1250 South Collegeville Road
Collegeville, Pennsylvania 19426, US
PHELAN, James P.
1250 South Collegeville Road
Collegeville, Pennsylvania 19426, US
VANHEYST, Michael D.
1250 South Collegeville Road
Collegeville, Pennsylvania 19426, US
ROWLEY, Ann M.
1250 South Collegeville Road
Collegeville, Pennsylvania 19426, US
SANFORD, Amberly B.
1250 South Collegeville Road
Collegeville, Pennsylvania 19426, US
YU, Hongyi
1250 South Collegeville Road
Collegeville, Pennsylvania 19426, US
JONES, Brian T.
7000 Shoreline Court
South San Francisco, California 94080, US
TAYGERLY, Joshua P.G.
7000 Shoreline Court
South San Francisco, California 94080, US
SEVERANCE, Daniel L.
8439 Torrell Way
San Francisco, California 92126, US
RYAN, Jonathon S.
7000 Shoreline Court
South San Francisco, California 94080, US
ALAM, Muzaffar
7000 Shoreline Court
South San Francisco, California 94080, US
FLEURY, Melissa
7000 Shoreline Court, Suite 350
South San Francisco, California 94080, US
MCFADDEN, Ryan M.
7000 Shoreline Court
Suite # 350
South San Francisco, California 94080, US
SIMONOVICH, Scott P.
4015 Linwood Avenue
Oakland, California 94602, US
Priority Data
63/505,508
01.06.2023
US
63/583,600
19.09.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 7431 | |
| EPO | Filing, Examination | 24112 | |
| Japan | Filing | 531 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 13035 |
Total: 45716 USD
Abstract[English]
Disclosed herein are certain chemical compounds of Formula (I): that inhibit Werner Syndrome ATP dependent helicase enzyme (WRN) activity, in particular inhibit WRN helicase domain activity and are therefore useful in treating cancers treatable by inhibition of WRN, including cancers characterized by microsatellite instability (MSI) and/or defective DNA mismatch repair system (dMMR). Also, disclosed are pharmaceutical compositions comprising such compounds, methods of using such compounds, and methods making the same.[French]
L'invention concerne certains composés chimiques de formule (I) : qui inhibent l'activité de l'enzyme hélicase dépendante de l'ATP du syndrome de Werner (WRN), en particulier inhibent l'activité du domaine de l'hélicase WRN et sont par conséquent utiles dans le traitement de cancers pouvant être traités par inhibition de WRN, y compris des cancers caractérisés par une instabilité des microsatellites (MSI) et/ou un système de réparation de mésappariement d'ADN défectueuse (dMMR). L'invention concerne également des compositions pharmaceutiques comprenant de tels composés, des procédés d'utilisation de tels composés, et des procédés de fabrication de ceux-ci.